Q-omics provides the consensus-scored COX7C profile across patient tissues and cancer cell-line models. COX7C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, COX7C is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, COX7C protein abundance shows 27,814 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, COAD, and GBM as cancer lineages where COX7C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX7C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX7C survival associations across molecular data types. COX7C RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX7C RNA expression–survival associations across cancer types. High COX7C expression shows unfavorable associations in UCS, LUAD, STAD, UVM and SCLC, but favorable associations in MESO. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCS as the clearest survival context for COX7C RNA expression.
This table summarizes COX7C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COX7C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX7C shows lower tumor expression in COAD, HNSC, STAD and BLCA and higher tumor expression in LIHC and KIRC. The COAD box plot shows higher COX7C RNA expression in normal versus tumor tissue (log2 FC = −0.466, t-test p < 0.001).
This table shows molecular features associated with COX7C in patient tissues and cancer cell lines. In patient samples, COX7C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, COX7C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
